Informação sobre produto
- (5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
- (-)-cis-6(S)-Phenyl-5(R)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
- (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]tetralin-2-ol
- (5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
- (5R-cis)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol
- 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-
- 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R-cis)-
- Cp-336,156
Lasofoxifene is a selective inhibitor of the cell cycle kinase, CDK4 and CDK6. The drug has been shown to inhibit the proliferation of cancer cells in vitro in human breast cancer cell lines. It also inhibits cell proliferation in vivo by inhibiting the proliferation of cancer cells that have been transplanted into mice. Lasofoxifene has also been shown to inhibit the growth of prostate cancer cells and may be useful for treating neurodegenerative disorders such as Alzheimer's disease.